Navigation Links
SynergEyes, Inc. Raises $13.3 Million in 'Series C' Financing
Date:2/6/2009

CARLSBAD, Calif., Feb. 6 /PRNewswire/ -- SynergEyes, Inc., the high Dk hybrid contact lens manufacturer, announced today the closing of $13.3 million in Series C financing to fund the development and clinical trials for next-generation hybrid contact lens products and to expand sales and marketing efforts globally.

De Novo Ventures of Palo Alto, CA, led this round as well as SynergEyes' Series B round. Bio-Star Private Equity Fund joined Series A and B investors: Alloy Ventures, Delphi Ventures, InnoCal Venture Capital and Windward Ventures as a new investor.

Based in Carlsbad, CA, SynergEyes has developed a new type of contact lens that combines two materials -- a rigid gas permeable center and a soft, hydrophilic outer skirt. The result is a durable "hybrid" lens for patients seeking crisp, clear vision and the all-day comfort of a soft lens.

"SynergEyes sincerely appreciates the continued commitment of our venture capital partners and their support of the vision and mission of SynergEyes. Their investment will ensure that the millions of patients in need of our technology will have access to the many features and benefits only a hybrid contact lens can offer," said Paul Kammann, CFO of SynergEyes, Inc.

"SynergEyes hybrid contact lenses represent a significant advancement in the contact lens industry and give eye care professionals a one-of-a-kind tool to satisfy one of the largest growing patient categories in the world," said Jim Ham, CEO for SynergEyes, Inc. "SynergEyes has demonstrated substantial revenue growth since market introduction in 2006. Our next-generation products will re-define state-of-the-art in the vision correction industry."

Jay Watkins, managing director of De Novo Ventures, expressed his firm's continued support for SynergEyes: "SynergEyes continues to demonstrate significant progress towards becoming a world-class vision care company. Hybrid contact lenses address a critical patient need and we are extremely pleased to continue our strong partnership with this innovative company."

The newest SynergEyes investor, Bio-Star Private Equity Fund, believes the company has the potential to deliver a truly transformational vision correction product. "During the due diligence process, our firm realized the compelling value proposition SynergEyes offers not only patients, but also eye care practitioners," said Renee Masi, Managing Member of BioStar. "The market potential for a product that can offer all the benefits of a rigid and soft contact lens without any of the disadvantages is tremendous."

Incorporating patented HyperBond(TM) technology and HydrolEyes(TM) surface science, the SynergEyes lenses with FDA market clearance include SynergEyes(R) A for naturally occurring ametropia, targeting patients with astigmatism, current gas permeable lens wearers, and patients demanding optimized vision; the SynergEyes(R) KC for keratoconus; the SynergEyes(R) Multifocal lens for presbyopia; and the SynergEyes(R) PS for post-surgery and post-trauma refractive errors.

    Contact:

    Kellie Kaseburg
    Vice President of Global Marketing
    kkaseburg@synergeyes.com
    877.SEE.2012
   http://www.synergeyes.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE SynergEyes, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Globus Medical Raises $110 Million in Series E Financing Round
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
4. Romark Laboratories Raises $18 Million in Institutional Financing
5. Light Sciences Oncology Raises $40.1 Million in Series C Financing
6. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
7. ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing
8. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
9. Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million
10. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
11. Atritech Announces Completion of a $22 Million Equity Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... IRVING, Texas , Oct. 11, 2017  Caris ... science focused on fulfilling the promise of precision medicine, ... Institute has joined Caris, Precision Oncology Alliance™ (POA) as ... leading cancer centers, the St. Jude Crosson Cancer Institute ... to advance the use of tumor profiling, making cancer ...
(Date:10/10/2017)... 2017   West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today shared the results of a study ... the intradermal administration of polio vaccines. The study results ... May 2017 by Dr. Ondrej Mach , Clinical ... Organization (WHO), and recently published in the journal ...
(Date:10/4/2017)... the Centers for Disease Control and Prevention (CDC), influenza vaccination should ... helping communities across Massachusetts , Connecticut ... shots through the end of the month. *Some exclusions apply ... ... is by the end of October, according to the Centers for Disease ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
(Date:10/12/2017)... , ... October 12, 2017 , ... On Saturday, October ... treadmill relay – Miles by Moonlight to raise money for the American Heart Association ... more. , Teams will work together to keep their treadmills moving for 5 ...
(Date:10/12/2017)... ... 2017 , ... Vohra Chief Medical Officer Dr. Shark Bird, ... nursing facility medical directors and other clinicians at various events in October. His ... many of these conferences we get to educate other physicians, facility nurses, corporate ...
Breaking Medicine News(10 mins):